MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 02-28-2026
Ultragenyx Pharmaceutical Total Shareholders Equity 2011-2026 | RARE
Annual Total Shareholders Equity Ultragenyx Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -80 M | 255 M | 275 M | 352 M | 923 M | 1.15 B | 654 M | 609 M | 383 M | 474 M | 531 M | 185 M | -74.8 M | -27 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.15 B | -80 M | 401 M |
Quarterly Total Shareholders Equity Ultragenyx Pharmaceutical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.16 M | 151 M | 144 M | 255 M | 347 M | 432 M | 140 M | 275 M | 31.7 M | 129 M | 220 M | 352 M | 469 M | 678 M | 796 M | 923 M | 934 M | 972 M | 1.05 B | 1.15 B | 666 M | 696 M | 609 M | 654 M | 727 M | 820 M | 887 M | 609 M | 609 M | 609 M | 609 M | 383 M | 383 M | 383 M | 383 M | 474 M | 474 M | 474 M | 474 M | 531 M | 531 M | 531 M | 531 M | 185 M | 185 M | 185 M | 185 M | -74.8 M | -74.8 M | -74.8 M | -74.8 M | -27 M | - | - | - | -7.96 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.15 B | -74.8 M | 433 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Xeris Pharmaceuticals
XERS
|
13.7 M | $ 6.03 | -1.55 % | $ 885 M |  USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
UroGen Pharma Ltd.
URGN
|
-105 M | $ 19.2 | -11.52 % | $ 554 M |  Israel |
 |
uniQure N.V.
QURE
|
199 M | $ 10.89 | -30.36 % | $ 530 M |  Niderland |
 |
GT Biopharma
GTBP
|
5.79 M | $ 0.47 | -2.41 % | $ 892 K | USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | Canada |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-160 M | $ 3.36 | 0.86 % | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.19 B | $ 29.16 | -3.54 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Alector
ALEC
|
30.6 M | $ 2.19 | -9.77 % | $ 226 M | USA |
 |
Entera Bio Ltd.
ENTX
|
6.66 M | $ 1.38 | -0.72 % | $ 63.3 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
124 M | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Evogene Ltd.
EVGN
|
56.9 M | $ 0.84 | -4.24 % | $ 27.9 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
459 M | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
AbbVie
ABBV
|
-3.27 B | $ 233.57 | 0.64 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
299 M | - | - | $ 8.14 B | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
AIM ImmunoTech
AIM
|
38.5 M | $ 0.8 | -11.6 % | $ 38.5 M | USA |
 |
Aptorum Group Limited
APM
|
21.1 M | $ 0.83 | 5.37 % | $ 4.53 M | China |
 |
Apellis Pharmaceuticals
APLS
|
370 M | $ 20.67 | -1.38 % | $ 2.61 B | USA |